Omeros Corporation

438 articles with Omeros Corporation

• Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020

  5/5/2020

  Omeros Corporation, announced that the company will issue its first quarter financial results for the period ended March 31, 2020, on Monday, May 11, 2020, after the market closes.

• Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA

  3/2/2020

  Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), markedly exceeding the FDA-agreed threshold for the primary efficacy endpoint.

• Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results

  3/2/2020

  – Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market

• Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020

  2/24/2020

  Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019, on Monday, March 2, 2020, after the market closes.

• Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors

  2/11/2020

  Feb. 11, 2020 13:30 UTC -- Zumwalt Also to Serve as Consultant, Bringing Extensive Capital Markets Background to Omeros -- SEATTLE--( BUSINESS WIRE )-- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of Amazon.com, Inc., to Omeros’ Board of Directors. He will also serve in a consulting role at Omeros. Mr. Zumwalt brings significant expertise in developing comprehensive business relationships with major banks and fin

• Omeros’ Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors

  12/16/2019

  This presentation included new data from human ex vivo studies demonstrating that GPR174 inhibition results in downregulation of checkpoint and tumor-promoting factors.

• Omeros Announces Full Exercise and Closing of Underwriter’s Option to Purchase Additional Shares

  12/13/2019

  Omeros Corporation (Nasdaq: OMER) (“Omeros”), announced today the full exercise and closing of the sale of 572,518 shares of common stock to the underwriter of its previously announced public offering pursuant to the underwriter’s option under the underwriting agreement to purchase additional shares of common stock.

• Omeros to Present GPR174 Data at the European Society for Medical Oncology 2019 Immuno-Oncology Congress in Geneva

  12/10/2019

  The presentation will include new findings from human T-cells demonstrating that GPR174 inhibition results in downregulation of checkpoint and tumor promoting factors.

• Omeros Announces Pricing of Upsized Public Offering of Common Stock

  12/5/2019

  The offering is expected to close on or about December 9, 2019, subject to the satisfaction of customary closing conditions

• Omeros Announces Proposed Public Offering of Common Stock

  12/4/2019

  Omeros Corporation announced that it has commenced a registered underwritten public offering of its common stock.

• Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab

  12/4/2019

  Omeros Corporation (Nasdaq: OMER) today announced positive data from its pivotal clinical trial of the company’s novel investigational complement inhibitor narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a frequently lethal complication of HSCT.

• Omeros’ New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online

  11/20/2019

  The positively received and well-attended presentation about the company’s cell-based and animal studies related to its newly discovered cancer immunity axis was made by Marc Gavin, Ph.D., Omeros’ Director of Immunology.

• Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston

  11/19/2019

  Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in animals.

• Omeros Corporation Reports Third Quarter 2019 Financial Results

  11/12/2019

  Omeros Corporation announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2019.

• Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy

  11/8/2019

  Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled “Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses” at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy, which is being held November 17 - 20, 2019 in Boston, Massachusetts.

• Omeros Scientists Win 2019 Prix Galien Research Award

  11/7/2019

  Prestigious Prize Conferred for GPCR Program Discoveries

• Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019

  11/6/2019

  Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019, on Tuesday, November 12, 2019, after the market closes.

• Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain

  11/4/2019

  Study Demonstrates Opioid-Sparing Requirement of OMIDRIA for CMS Packaging Exclusion

• Omeros’ Narsoplimab Receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan Required for MAA Submission

  10/29/2019

  Includes Deferral for PIP Completion Until After Approval of Marketing Authorization Application

• Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA

  10/28/2019

  Rolling Submission of the Remaining BLA Sections Continues On Track for Scheduled Completion 1H 2020